Subsidy Information and Financing Scheme MAFEnzalutamide Capsule 40 mg 1) Enzalutamide in combination with androgen deprivation therapy (ADT) for treating patients with h... See all × MAFEnzalutamide Capsule 40 mg 1) Enzalutamide in combination with androgen deprivation therapy (ADT) for treating patients with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC). 2) Enzalutamide in combination with androgen deprivation therapy (ADT) for treating patients with metastatic hormone-sensitive prostate cancer (mHSPC). 3) Enzalutamide in combination with androgen deprivation therapy (ADT) for treating patients with metastatic castration-resistant prostate cancer (mCRPC). MSHLEnzalutamide Capsule 40 mg 1) Enzalutamide in combination with androgen deprivation therapy (ADT) for treating patients with h... See all × MSHLEnzalutamide Capsule 40 mg 1) Enzalutamide in combination with androgen deprivation therapy (ADT) for treating patients with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC). 2) Enzalutamide in combination with androgen deprivation therapy (ADT) for treating patients with metastatic castration-resistant prostate cancer (mCRPC). 3) Enzalutamide in combination with androgen deprivation therapy (ADT) for treating patients with metastatic hormone-sensitive prostate cancer (mHSPC).
Drug Guidance for Subsidy 16/09/2025 Talazoparib in combination with enzalutamide for treating HRR gene-mutated metastatic castration-resistant prostate cancer NRThe Ministry of Health’s Drug Advisory Committee has not recommended talazoparib in combinat... See all × 16/09/2025 Talazoparib in combination with enzalutamide for treating HRR gene-mutated metastatic castration-resistant prostate cancer NRThe Ministry of Health’s Drug Advisory Committee has not recommended talazoparib in combination with enzalutamide for inclusion on the MOH List of Subsidised Drugs for treating homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer. The decision was based on the low clinical need, uncertain or unfavourable cost-effectiveness compared with treatment alternatives, and the unacceptable price-volume agreement proposed by the company. Clinical indication, subsidy class and MediShield Life claim limit for talazoparib plus enzalutamide are provided in the Annex.
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Capsule 40 mg Changi General Hospital Khoo Teck Puat Hospital National Cancer Centre Ng Teng Fong General Hospital National University Hospital Sengkang General Hospital Singapore General Hospital Tan Tock Seng Hospital Woodlands Health Campus